Business Wire

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, ...

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neur…

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Clinical Trials Arena on MSN

Tempus Broadens Collaboration With BMS for Clinical Trials

The initiative is initially supporting solid tumour oncology projects, focusing on indications such as colon and lung.

Here’s Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 ...

Tempus AI, Bristol Myers Squibb expand AI-driven clinical trial efforts

Tempus AI Inc. TEM announced a new collaboration initiative with Bristol Myers Squibb Co. BMY aimed at improving clinical ...
Seeking Alpha

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

The collaboration follows FDA 510(k) clearance for eyonis ® LCS and aims to integrate high-performance lung cancer screening detection and diagnosis device into the clinical workflow through the ...
Benzinga.com

Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says

Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases ...

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI, Inc. ("Tempus") (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and ...
The Caledonian-Record

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus estimates that the net proceeds from the Offering will be approximately $384.1 million (or approximately $441.9 million if the initial purchasers exercise their option to purchase additional ...
Business Wire

Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley ...
Morningstar

Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s ...
Morningstar

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States

Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States The collaboration follows FDA 510(k) clearance for eyonis® LCS ...